Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M1,341Revenue $M9.8Net Margin (%)-1,732.9Altman Z-Score13.6
Enterprise Value $M1,181EPS $-3.4Operating Margin %-1,747.8Piotroski F-Score2
P/E(ttm)--Beneish M-Score-4.0Pre-tax Margin (%)-1,732.9Higher ROA y-yN
Price/Book6.610-y EBITDA Growth Rate %-4.9Quick Ratio5.7Cash flow > EarningsY
Price/Sales3615-y EBITDA Growth Rate %28.7Current Ratio5.7Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-57.5Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-66.9Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M41.5ROIC % (ttm)-506.2Gross Margin Increase y-yN

Gurus Latest Trades with SRPT

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
SRPTGeorge Soros 2014-12-31 Sold Out -0.05%$12.6 - $23.56
($16.84)
$ 31.7689%Sold Out0
SRPTGeorge Soros 2014-09-30 Reduce-0.08%$19.9 - $30.27
($22.49)
$ 31.7641%Reduce 52.21%325,000
SRPTGeorge Soros 2014-06-30 Add0.14%$22.18 - $38.91
($31.64)
$ 31.760%Add 2620.00%680,000
SRPTGeorge Soros 2014-03-31 Reduce-0.04%$17.91 - $30.29
($25.36)
$ 31.7625%Reduce 89.27%25,000
SRPTGeorge Soros 2013-12-31 Reduce-0.22%$12.89 - $53.81
($29.58)
$ 31.767%Reduce 64.98%233,000
SRPTGeorge Soros 2013-09-30 Add0.12%$30.906 - $47.97
($38.37)
$ 31.76-17%Add 56.28%665,274
SRPTGeorge Soros 2013-03-31 Add0.08%$23.97 - $36.95
($28.83)
$ 31.7610%Add 82.54%413,329
SRPTGeorge Soros 2012-12-31 Add0.05%$14.99 - $44.93
($26.74)
$ 31.7619%Add 184.13%226,429
SRPTFirst Eagle Investment 2012-03-31 Sold Out $4.44 - $9.6
($6.51)
$ 31.76388%Sold Out0
SRPTFirst Eagle Investment 2011-12-31 Reduce$3.24 - $6.54
($4.96)
$ 31.76540%Reduce 83.33%8,333
SRPTFirst Eagle Investment 2011-09-30 Add$6.3 - $9.9
($7.86)
$ 31.76304%Add 50.00%50,000
SRPTFirst Eagle Investment 2011-06-30 Buy $8.1 - $11.22
($9.69)
$ 31.76228%New holding33,333
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

SRPT is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!


SRPT: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Kaye Edward M. MDSVP & Chief Medical Officer 2015-02-27Buy800$11.82173.6 view
Christopher Nishan GarabedianPresident and CEO 2015-02-27Buy800$11.82173.6 view
CHASE ANTHONY RDirector 2013-11-14Buy10,000$13.95131.83 view
Aphale JayantSVP Technical Operations 2013-11-12Sell15,933$12.56157.48 view
BEHRENS M KATHLEENDirector 2013-09-16Buy6,500$37.04-12.69 view
HODGMAN JOHNDirector 2013-09-03Sell5,556$34.97-7.52 view
CHASE ANTHONY RDirector 2013-08-22Buy3,500$32.68-1.04 view
Mahatme SandeshSenior Vice President, CFO 2013-08-20Buy5,000$31.13.99 view
Price Ben GilDirector 2013-08-19Buy500$31.183.72 view
CHASE ANTHONY RDirector 2013-06-14Buy10,000$38.5-16 view

Quarterly/Annual Reports about SRPT:

News about SRPT:

Articles On GuruFocus.com
Sarepta Therapeutics Inc (SRPT) Will File NDA; Analysts Have Mixed Ratings May 20 2015 
Wednesday’s Pre-Market Insights: Yahoo! Inc. (YHOO), Sarepta Therapeutics Inc (SRPT), Time Warner May 20 2015 
Steven Cohen Keeps on Buying Biotechnological Companies May 04 2015 
Ebola: Is The Cure Out There? Oct 14 2014 
Insiders Are Buying Fate Therapeutics Oct 09 2013 
comment on SRPT Mar 16 2013 
comment on SRPT Mar 16 2013 
comment on SRPT Feb 16 2013 

More From Other Websites
Sarepta Therapeutics Announces New England Journal of Medicine Publication of Phase I Clinical Data... Jul 30 2015
Sarepta Therapeutics to Announce Second Quarter 2015 Financial Results and Recent Corporate... Jul 30 2015
Sarepta Therapeutics to Announce Second Quarter 2015 Financial Results and Recent Corporate... Jul 30 2015
Sarepta Therapeutics Announces New England Journal of Medicine Publication of Phase I Clinical Data... Jul 22 2015
​Short sellers retreat from Sarepta and OvaScience Jul 20 2015
FDA Closing In on November Expert Panel Date for BioMarin, Sarepta Drugs Jul 20 2015
​Sarepta makes plans to start late-stage tests of two more Duchenne drugs Jul 17 2015
Sarepta Soars on FDA Submission for Duchenne Drug Jul 16 2015
Sarepta Therapeutics One Step Closer to Drug Approval Jul 03 2015
SAREPTA THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers Jul 02 2015
The Zacks Analyst Blog Highlights: Celgene, Juno Therapeutics, Intercept, BioMarin and Sarepta -... Jul 02 2015
Cramer Worried About Airline Overcapacity, Hints at Surprise McDonald's Piece Jul 01 2015
Biotech Stock Roundup: Juno-Celgene In Immunotherapy Deal, BioMarin/Sarepta DMD Drugs Progress -... Jul 01 2015
Sarepta Hires ex-Genzyme Head Henri Termeer as Adviser Jul 01 2015
Sarepta Therapeutics Appoints Henri Termeer as Advisor to the Company Jul 01 2015
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Jun 30 2015
SAREPTA THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Amendments... Jun 30 2015
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Jun 30 2015

Add Notes, Comments

If you want to ask a question, or report a bug, please create a support ticket.

User Comments

No comment yet
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK